Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm by Site — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site

Other

Neoplasm by Site

CI-CAN-00000003Explore in graph →

Non-malignant20,504 active trials253 approved drugs3,568 evidence items

NCIt: C3263
MeSH: D009371

Overview
Statistics
Survival
Genomics537
Variants & evidence3568
Drugs398
Trials92622
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,460)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,676–3,700 of 4,460 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.
· Ann Oncol · 2014 · PMID 24504448 · validated civic_curation pubmed
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
· Clin Cancer Res · 2016 · PMID 26787751 · validated civic_curation pubmed
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.
· Pigment Cell Melanoma Res · 2015 · PMID 26072686 · validated civic_curation pubmed
Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.
· Ann Oncol · 2016 · PMID 26787234 · validated civic_curation pubmed
mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.
· J Clin Oncol · 2011 · PMID 21189378 · validated civic_curation pubmed
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
· Lung Cancer · 2015 · PMID 25982012 · validated civic_curation pubmed
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
· Onco Targets Ther · 2016 · PMID 27445490

Showing 3,676–3,700 of 4,460 publications

← Previous
1
…
147
148
149
…
179
Next →

· validated civic_curation

Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

· Ann Oncol · 2016 · PMID 27022066 · validated civic_curation pubmed

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.

· J Thorac Oncol · 2016 · PMID 26845194 · validated civic_curation pubmed

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

· J Thorac Oncol · 2016 · PMID 27343442 · validated civic_curation pubmed

Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.

· J Hematol Oncol · 2014 · PMID 24422672 · validated civic_curation pubmed

Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.

· Case Rep Oncol Med · 2015 · PMID 25692060 · validated civic_curation pubmed

MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

· J Clin Endocrinol Metab · 2015 · PMID 25625803 · validated civic_curation pubmed

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

· J Thorac Oncol · 2017 · PMID 27664533 · validated civic_curation pubmed

Cytogenetic findings in liposarcoma correlate with histopathologic subtypes.

· Cancer · 1992 · PMID 1568170 · validated civic_curation pubmed

Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions.

· Eur J Hum Genet · 2008 · PMID 18478040 · validated civic_curation pubmed

PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

· Cancer Res · 1997 · PMID 9331072 · validated civic_curation pubmed

Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.

· Ann Otol Rhinol Laryngol · 2017 · PMID 28061634 · validated civic_curation pubmed

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

· Ann Oncol · 2015 · PMID 26269204 · validated civic_curation pubmed

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

· Cancer Res · 2005 · PMID 15930265 · validated civic_curation pubmed

S768I Mutation in EGFR in Patients with Lung Cancer.

· J Thorac Oncol · 2016 · PMID 27211795 · validated civic_curation pubmed

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

· Cancer Discov · 2015 · PMID 26216294 · validated civic_curation pubmed

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.

· PLoS One · 2016 · PMID 27045755 · validated civic_curation pubmed

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.

· Oncotarget · 2017 · PMID 28978004 · validated civic_curation pubmed

Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.

· Cancer Biol Ther · 2018 · PMID 27466707 · validated civic_curation pubmed